Skip to main content
TipRanks
Go Ultimate75% OFF

Valneva (AYJ0) Q2 2026 Earnings Report

2 Followers

DE:AYJ0 Q2 2026 EPS Results

Actual EPS
-EUR 0.35
Consensus EPS
-EUR 0.18
Beat/Miss
Missed by -EUR 0.17
One Year Ago EPS
-EUR 0.15

DE:AYJ0 Q2 2026 Revenue Results

Actual Revenue
EUR 36.37M
Expected Revenue
EUR 43.16M
Beat/Miss
Missed by -EUR 6.79M
YoY Revenue Growth
-25.85%

Earnings Announcement Details

Quarter
Q2 2026
Date
08/13/2026
Time
Before Open
Conference Call
Thursday, August 13, 2026
DE:AYJ0 Upcoming Earnings

Valneva's next earnings date is estimated for November 24, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

DE:AYJ0 Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 13, 2026|% Change Since:6.09%|
Earnings Call Sentiment|Negative

The call presented meaningful operational and pipeline positives — notably a solid cash position (EUR 121.5m), active cost‑saving restructuring, regulatory progress and encouraging clinical signals for the Lyme vaccine, and commercial/partner milestones for IXCHIQ and Shigella. However, H1 2026 was marked by sizeable top‑line declines (total revenue -32.6%), margin deterioration, material one‑off manufacturing and inventory charges (EUR 9.7m cancellation fee, EUR 4.5m impairment), and a large widening of operating losses (EUR 49.9m). While management expects improvements in H2 driven by restructuring, DoD contract extension and reversal of one‑offs, the negative financial trends in H1 outweigh the positives and leave the company dependent on regulatory success for the Lyme vaccine to materially change its financial trajectory.

Company Guidance

Valneva reiterated 2026 guidance of product sales €135–150m and total revenues €145–160m, saying H1 pacing is in line with that outlook; H1 results included product sales €64.0m (vs €91.0m a year ago) and total revenues €65.8m (vs €97.6m), cash €121.5m (up from €109.6m at FY2025) and cash used in operations €13.7m (vs €10.9m), an operating loss of €49.9m (vs €16.8m) and an adjusted EBITDA loss of €40.1m (vs €6.0m). Cost of goods and services were €59.5m (vs €47.2m), including a €9.7m cancellation‑fee provision and a €4.5m inventory impairment; IXIARO sales €44.0m (vs €54.7m) with 56.4% gross margin (vs 65.5%), DUKORAL €14.7m (vs €17.4m) with 24.7% margin (vs 52.9%), IXCHIQ €4.4m (vs €7.5m) and third‑party products €1.0m (vs €11.4m). Operating expenses showed cuts—R&D €30.2m (vs €32.4m), marketing & distribution €13.5m (vs €20.3m), G&A €15.4m (vs €19.0m)—with a one‑time restructuring cost of €3.2m; management expects product‑related gross margin, P&L and cash flow to improve in H2 after non‑recurring effects, anticipates a new U.S. DoD IXIARO contract in the coming months, and says the company could become financially self‑sustainable starting in 2026 pending regulatory approval and Pfizer commercialization of the Lyme vaccine.

  • Strong cash position and liquidityCash at June 30, 2026 of EUR 121.5 million versus EUR 109.6 million at FY2025 end, providing a stronger liquidity buffer to execute restructuring and near-term operations.
  • Confirmed full-year guidanceCompany reaffirmed 2026 guidance: product sales of EUR 135–150 million and total revenues of EUR 145–160 million, maintaining market expectations despite H1 volatility.
  • Restructuring program underway with near-term savingsRestructuring implemented in June with one-time costs of EUR 3.2 million and workforce reductions; management expects positive P&L and cash flow impact in H2 2026 and beyond.
  • Lyme vaccine clinical and regulatory progressVLA15 (LB6V) demonstrated point efficacy >70% with a clinically meaningful effect; a second pre-specified analysis showed a 95% CI lower bound >20%. Pfizer filed with the EMA and expects regulatory decisions within ~12 months, and remains optimistic about the program's prospects.
  • Commercial and partner progress for IXCHIQ in BrazilPilot Vaccination Campaign in Brazil has vaccinated >50,000 adults (target minimum 100,000), and local manufacturing by partner Butantan has been approved with drug-substance shipments recorded — potential incorporation into Brazil's public health system expected.
  • Pipeline expansion and Shigella in-licenseIn-licensed a tetravalent Shigella candidate with two ongoing studies (infant immunogenicity/safety and adult human challenge); topline results expected in the coming months to inform next development steps.
  • Cost discipline across operating expensesR&D declined to EUR 30.2m from EUR 32.4m (-6.8%); marketing & distribution down to EUR 13.5m from EUR 20.3m (-33.5%); G&A down to EUR 15.4m from EUR 19.0m (-18.9%), reflecting reprioritization and efficiency efforts.
  • Ongoing commercial opportunities (DoD and future contracts)Shipments to U.S. Department of Defense continued under 1-year contract; company expects to sign a new DoD contract and begin recording sales under it in H2 2026, supporting future revenue visibility.

DE:AYJ0 Earnings History

DE:AYJ0 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Nov 24, 20262026 (Q3)-0.18--0.49――
Aug 13, 20262026 (Q2)-0.18-0.35-0.15-142.59% (-0.21)
May 13, 20262026 (Q1)-0.13-0.37-0.13-197.14% (-0.25)
Mar 18, 20262025 (Q4)-0.32-0.62-0.44-41.98% (-0.18)
Nov 20, 20252025 (Q3)-0.29-0.49-0.1-394.55% (-0.39)
Aug 12, 20252025 (Q2)-0.29-0.15-0.3457.70% (+0.20)
May 07, 20252025 (Q1)-0.31-0.130.79-115.84% (-0.92)
Mar 20, 20252024 (Q4)-0.19-0.44-0.464.52% (+0.02)
Nov 07, 20242024 (Q3)-0.24-0.10-0.4879.52% (+0.38)
Aug 13, 20242024 (Q2)-0.31-0.34-0.17-100.52% (-0.17)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed